DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies

Information source: University of Chicago
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Unspecified Adult Solid Tumor, Protocol Specific

Intervention: capecitabine (Drug); celecoxib (Drug); pharmacological study (Other); laboratory biomarker analysis (Other); pharmacogenomic studies (Other)

Phase: N/A

Status: Recruiting

Sponsored by: University of Chicago

Official(s) and/or principal investigator(s):
Manish R. Sharma, M.D., Principal Investigator, Affiliation: University of Chicago Comprehensive Cancer Center


This clinical trial studies capecitabine and celecoxib in treating patients with solid malignancies that are metastatic or cannot be removed by surgery. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving capecitabine and celecoxib together may be an effective treatment for solid malignancies.

Clinical Details

Official title: A Drug-drug Interaction Study of Capecitabine and Celecoxib in Patients With Advanced Solid Malignancies

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: AUC of celecoxib on combination therapy (day 14) and AUC of celecoxib on celecoxib monotherapy(day 7)

Secondary outcome:

CYP2C9 genotype

Response rate

Drug-related toxicities

PK drug interaction model

Detailed description: PRIMARY OBJECTIVES: I. To compare steady state pharmacokinetics (PK) (primarily minimum concentration [Cmin], maximum concentration [Cmax], and area under the curve [AUC]) of celecoxib on day 7 of monotherapy versus on day 14 of concomitant administration with capecitabine. SECONDARY OBJECTIVES: I. To develop a celecoxib PK drug interaction model using longitudinal data and determine whether the results are concordant with results from the primary objective. II. To assess the impact of known cytochrome P450 2C9 (CYP2C9) pharmacogenetic variants with reduced enzyme activity (CYP2C9*2 and *3) on the between subject variability in celecoxib PK. III. To assess tumor response by the Response Evaluation Criteria In Solid Tumors (RECIST, version 1. 1) and explore whether there is any correlation between celecoxib PK and response. IV. To assess toxicity by the Common Terminology Criteria for Adverse Events (CTCAE, version 4. 0) and explore whether there is any correlation between celecoxib PK and toxicities related to either celecoxib or capecitabine. OUTLINE: Patients receive celecoxib orally (PO) twice daily (BID) for 7 days (course 0) and then on days 1-21 of course 1 and all subsequent courses. Patients also receive capecitabine PO BID on days 1-14 beginning in course 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Histologically or cytologically confirmed solid tumor that is metastatic or

unresectable and for which standard curative or palliative measures do not exist or are no longer effective

- Eastern Cooperative Oncology Group (ECOG) performance status =< 1

- Life expectancy > 3 months

- Absolute neutrophil count (ANC) >= l500/ul

- Hemoglobin >= 9g/dL

- Platelets >= 100,000/ul

- Creatinine within institutional normal limits or glomerular filtration rate >= 50

mL/min/1. 73 m^2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation

- Total bilirubin < 1. 5 x upper limit of normal

- Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate

transaminase (SGPT) < 2. 5 x upper limit of normal for patients without liver metastases OR SGOT and SGPT < 5 x upper limit of normal for patients with liver metastases

- Measurable or non-measurable disease will be allowed

- Women of child-bearing potential and men must agree to use adequate contraception

(hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately

- Patients taking substrates of CYP2C9 should be encouraged to switch to alternative

drugs whenever possible, given the potential for drug-drug interactions with the study drugs

- Signed informed consent

Exclusion Criteria:

- Prior treatment with capecitabine and/or celecoxib is allowed; however, patients with

a documented history (at the time of enrollment) of >= grade 3 toxicities with capecitabine or celecoxib are excluded

- Patients taking any of the following drugs are excluded: inducers or inhibitors of

CYP2C9, warfarin, aspirin, corticosteroids, or non-steroidal anti-inflammatory drugs (NSAIDs)

- History of myocardial infarction or stroke within the last 6 months, or history of

uncontrolled cardiovascular or cerebrovascular disease; a 12-lead electrocardiogram (ECG) will be performed during the screening period

- History of perforation or bleeding related to peptic ulcer disease

- History of hypersensitivity or allergy to study drugs, aspirin, sulfonamides, or


- Known poor metabolizers of CYP2C9 substrates

- Known deficiency of dihydropyrimidine dehydrogenase (DPD)

- Patients who have had chemotherapy, immunotherapy, or investigational anti-cancer

therapy within 4 weeks of starting study drug, or radiotherapy within 14 days of starting study drug, or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier

- Patients may not be receiving any other investigational agents or any concomitant

antineoplastic therapy, with the exception of androgen ablating agents (for patients with prior prostate cancer)

- Serious underlying medical or psychiatric illnesses that would, in the opinion of the

treating physician, substantially increase the risk for complications related to treatment; similarly, any unstable medical condition that in the opinion of the treating physician or study investigators, would interfere with determination of the study objectives

- Pregnancy or breastfeeding

- Major surgery within 4 weeks

Locations and Contacts

University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637-1470, United States; Recruiting
Manish R. Sharma, M.D., Phone: 773-834-0312, Email: msharma@medicine.bsd.uchicago.edu
Manish R. Sharma, Principal Investigator
Additional Information

Starting date: August 2012
Last updated: June 22, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017